RATIONALE AND OBJECTIVES: To investigate whether inflammatory activity can be evaluated by MRI with an intravascular compound (MS-325) in Desoxyribonuclease I (Dnase1)-deficient mice, which show classical symptoms of systemic lupus erythematosus. METHODS: Dnase1-deficient and normal mice (both groups n = 10) underwent MRI with a body weight adapted dose of MS-325 on a 1.5 T whole body scanner equipped with a dedicated surface coil. MR images of the kidneys and the aorta and signal to noise ratios prior and post contrast administration were compared with histopathology in all animals. RESULTS: Dnase1-knockout mice demonstrated aortic-wall enhancement and inhomogeneous-renal enhancement with significantly higher SNR values corresponding to microscopically proved inflammatory changes (P < 0.05). CONCLUSION: MS-325-enhanced MRI appears to be a sensitive tool for the detection of renal and vascular involvement in this animal model. In addition, this method may facilitate assessment of therapeutic approaches in patients with SLE in the future.
RATIONALE AND OBJECTIVES: To investigate whether inflammatory activity can be evaluated by MRI with an intravascular compound (MS-325) in Desoxyribonuclease I (Dnase1)-deficient mice, which show classical symptoms of systemic lupus erythematosus. METHODS:Dnase1-deficient and normal mice (both groups n = 10) underwent MRI with a body weight adapted dose of MS-325 on a 1.5 T whole body scanner equipped with a dedicated surface coil. MR images of the kidneys and the aorta and signal to noise ratios prior and post contrast administration were compared with histopathology in all animals. RESULTS:Dnase1-knockout mice demonstrated aortic-wall enhancement and inhomogeneous-renal enhancement with significantly higher SNR values corresponding to microscopically proved inflammatory changes (P < 0.05). CONCLUSION:MS-325-enhanced MRI appears to be a sensitive tool for the detection of renal and vascular involvement in this animal model. In addition, this method may facilitate assessment of therapeutic approaches in patients with SLE in the future.
Authors: Verónica Fuentes-Santamaría; Juan Carlos Alvarado; Susana Mellado; Pedro Melgar-Rojas; María Cruz Gabaldón-Ull; José J Cabanes-Sanchis; José M Juiz Journal: Front Aging Neurosci Date: 2022-04-05 Impact factor: 5.702